Trials / Completed
CompletedNCT04609670
Study of Radiolabeled ALXN2050 in Healthy Adult Males
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-ALXN2050 in Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 (\[14C\])-ALXN2050 in healthy adult males.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-ALXN2050 | A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally. |
Timeline
- Start date
- 2021-04-12
- Primary completion
- 2021-08-23
- Completion
- 2021-08-23
- First posted
- 2020-10-30
- Last updated
- 2023-01-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04609670. Inclusion in this directory is not an endorsement.